rHuEPO Hyporesponsiveness and Related High Dosages Are Associated with Hyperviscosity in Maintenance Hemodialysis Patients

Objective. Increased viscosity may increase the risk of thrombosis or thromboembolic events. Recombinant human erythropoietin (rHuEPO) is the key stone treatment in anemic ESRD patients with the thrombotic limiting side effect. We evaluated the influence of clinical and laboratory findings on plasma...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Erkmen Uyar, Mehtap, Toprak, Selami Kocak, Saglam, Hatice, Tutal, Emre, Bay, Meltem, Ilhan, Osman, Bal, Zeynep, Sezer, Siren
Materialtyp: Artigo
Språk:Inglês
Publicerad: Hindawi Publishing Corporation 2013
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3806397/
https://ncbi.nlm.nih.gov/pubmed/24198729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2013/792698
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk